首页 | 本学科首页   官方微博 | 高级检索  
     


Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab
Authors:Andrew M. Evens DO  MSc  Ann Vanderplas MS  Ann S. LaCasce MD  Allison L. Crosby MS  Auayporn P. Nademanee MD  Mark S. Kaminski MD  Gregory A. Abel MD  MPH  Michael Millenson MD  Myron S. Czuczman MD  Maria A. Rodriguez MD  Joyce Niland PhD  Andrew D. Zelenetz MD  PhD  Leo I. Gordon MD  Jonathan W. Friedberg MD  MSc
Affiliation:1. Division of Hematology/Oncology, Tufts University School of Medicine, , Boston, Massachusetts;2. Department of Biostatistics, City of Hope National Medical Center, , Duarte, California;3. Department of Medical Oncology, Dana‐Farber Cancer Institute, , Boston, Massachusetts;4. Department of Stem Cell Transplant, City of Hope National Medical Center, , Duarte, California;5. University of Michigan Cancer Center, , Ann Arbor, Michigan;6. Fox Chase Cancer Center, , Philadelphia, Pennsylvania;7. Roswell Park Cancer Institute, , Buffalo, New York;8. MD Anderson Cancer Center, , Houston, Texas;9. Memorial Sloan‐Kettering Cancer Center, , New York, New York;10. Division of Hematology/Oncology, Northwestern University, , Chicago, Illinois;11. Division of Hematology/Oncology, University of Rochester, James P. Wilmot Cancer Center, , Rochester, New York
Abstract:
Keywords:follicular lymphoma  prognostication  autologous transplantation  allogeneic transplantation  survival  rituximab  non‐Hodgkin lymphoma  stem cell transplantation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号